Related Experiment Video
Updated: Jan 20, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression
Si Sun1,2, Zhihuang Hu1,2, Shenglin Huang3
1Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai, 200032, China.
Objectives:
Recent research has classified lung adenocarcinoma patients with KRAS mutation into three subtypes by co-occurring genetic events in TP53 (KP subgroup), STK11/LKB1 (KL subgroup) and CDKN2A/B inactivation plus TTF-1 low expression (KC subgroup). The aim of this study was to identify valuable biomarkers by searching the candidate molecules that contribute to lung adenocarcinoma pathogenesis, especially KC subtype.
Materials And Methods:
We analyzed the publicly available database and identified the candidate REG4 using the E-GEOD-31210 dataset, and then confirmed by TCGA dataset. In addition, an independent cohort of 55 clinical samples was analyzed by quantitative real-time PCR analysis. Functional studies and RNA sequencing were performed after silencing the REG4 expression.
Results:
REG4, an important regulator of gastro-intestinal carcinogenesis, was highly expressed in KRAS mutant lung adenocarcinoma with low expression of TTF-1 (KC subtype). The results were validated both by gene expression analysis and immunohistochemistry study in an independent 55 clinical samples from Fudan University Shanghai Cancer Center. Further in vitro and in vivo functional assays revealed silencing REG4 expression significantly reduces cancer cell proliferation and tumorigenesis. Moreover, RNA sequencing and GSEA analysis displayed that REG4 knockdown might induce cell cycle arrest by regulating G2/M checkpoint and E2F targets.
Conclusion:
Our results indicate that REG4 plays an important role in KRAS-driven lung cancer pathogenesis and is a novel biomarker of lung adenocarcinoma subtype. Future studies are required to clarify the underlying mechanisms of REG4 in the division and proliferation of KC tumors and its potential therapeutic value.
Insights
Researchers identified REG4 as a key biomarker in KRAS-driven lung adenocarcinoma, particularly the KC subtype. Silencing REG4 reduced tumor growth, suggesting its therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Lung adenocarcinoma (LUAD) with KRAS mutation is classified into KP, KL, and KC subtypes based on co-occurring genetic events.
- The KC subtype is characterized by CDKN2A/B inactivation and low TTF-1 expression.
- Identifying specific molecular drivers is crucial for understanding LUAD pathogenesis, especially in the KC subtype.
Purpose of the Study:
- To identify novel biomarkers contributing to lung adenocarcinoma pathogenesis.
- To investigate the role of candidate molecules, particularly in the KC subtype of KRAS-mutant LUAD.
Main Methods:
- Analysis of public datasets (E-GEOD-31210, TCGA) to identify candidate molecules.
- Validation using quantitative real-time PCR in an independent cohort of 55 clinical samples.
- Functional studies including in vitro and in vivo assays after REG4 silencing, coupled with RNA sequencing and Gene Set Enrichment Analysis (GSEA).
Main Results:
- REG4, a regulator of gastrointestinal carcinogenesis, was found to be highly expressed in KRAS-mutant LUAD with low TTF-1 expression (KC subtype).
- Gene expression analysis and immunohistochemistry confirmed high REG4 expression in an independent clinical cohort.
- Silencing REG4 significantly reduced cancer cell proliferation and tumorigenesis, potentially by inducing cell cycle arrest via G2/M checkpoint and E2F targets.
Conclusions:
- REG4 plays a significant role in the pathogenesis of KRAS-driven lung cancer.
- REG4 is identified as a novel biomarker for a specific lung adenocarcinoma subtype.
- Further research is warranted to elucidate REG4's mechanisms in KC tumor division and proliferation and its therapeutic potential.
More Related Videos
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
Related Concept Videos
Indicators
Lung Capacity
Mechanical Ventilation I: Indication and Settings
Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
Bioequivalence of Drugs: Drugs with Multiple Indications
Cardiovascular Drugs: Classification based on Therapeutic Indications